Spots Global Cancer Trial Database for Compassionate Use Individual Request Program for GSK525762 in NUT Midline Carcinoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Compassionate Use Individual Request Program for GSK525762 in NUT Midline Carcinoma
Official Title: Compassionate Use Individual Request Program for GSK525762 in NUT Midline Carcinoma
Study ID: NCT03702036
Conditions
Interventions
Study Description
Brief Summary: Compassionate use access to molibresib/GSK525762 for eligible participant with NUT Midline Carcinoma; indication is a seriously debilitating or life-threatening disease.
Detailed Description: Investigational Product GSK525762 is an orally bioavailable small molecule that is a potent inhibitor of the binding of BET proteins to acetylated histones. Binding of GSK525762 induces squamous differentiation and inhibits proliferation of patient-derived NMC cell lines both in culture and in murine xenografts. Compassionate use access to molibresib is restricted to patients with confirmed diagnosis of NUT Midline Carcinoma.
Eligibility
Minimum Age: 16 Years
Eligible Ages: CHILD, ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Contact Details
Name: GSK Clinical Trials
Affiliation: GlaxoSmithKline
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
